<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00381303</url>
  </required_header>
  <id_info>
    <org_study_id>CR011869</org_study_id>
    <secondary_id>TMC114HIV3004</secondary_id>
    <nct_id>NCT00381303</nct_id>
  </id_info>
  <brief_title>GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.</brief_title>
  <official_title>GRACE: An Open-label, Multicenter Trial to Compare the Efficacy, Safety, and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race, When Administered in Combination With an Individually Optimized Background Regimen Over a 48-week Treatment Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tibotec, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate any differences in the effectiveness, safety, and
      tolerability of PREZISTA (darunavir; DRV) 600 mg, administered with ritonavir (RTV) 100 mg
      twice a day on virologic response (defined as a viral load (VL) of &lt; 50 copies/mL) over a
      48-week treatment period in HIV-positive women and men. Additional antiretroviral (ARV)
      agents will also be administered and will be chosen by the Investigator based on resistance
      testing and prior treatment history (referred to as the Optimized Background Regimen (OBR)).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label (doctors and patients know which drug is being
      administered), Phase IIIb clinical trial to evaluate differences in effectiveness, safety,
      and tolerability of darunavir/ritonavir by sex and/or race over a 48-week treatment period.
      This study will be conducted in HIV positive women and men who have been treated previously
      with antiretroviral therapy. This study will enroll 70% women and will be conducted in the
      U.S., Puerto Rico, Mexico and Canada in approximately 420 patients who will receive darunavir
      600 mg and ritonavir 100 mg twice daily. The primary objective of this study is to determine
      the percentage of patients who achieve virologic response, defined as a viral load (VL) of
      &lt;50 copies/mL at week 48. Secondary study objectives include comparisons of endpoints between
      women and men as well as race across multiple parameters including but not limited to change
      in CD4 count from baseline to week 48, time to loss of virologic response (TLOVR), changes in
      metabolic parameters (blood chemistry), etc.

      Within 4 weeks after the Screening Visit (initial visit with investigator to determine
      eligibility), the Investigator should have received all data required to determine the
      patient's eligibility and will construct the individual Optimized Background Regimen (OBR)
      that will be used during the treatment period in combination with darunavir/ritonavir for
      those patients enrolled in the study. The OBR will consist of additional antiretroviral (ARV)
      agents that will also be administered during the study chosen by the Investigator and based
      on resistance testing and prior treatment history. The study Sponsor will provide the
      following ARV agents, that may be used as options for the OBR: TMC 125 (investigational
      non-nucleoside reverse transcriptase inhibitor; NNRTI); Truvada (tenofovir/emtricitabine);
      Viread (tenofovir); Emtriva (emtricitabine); Zidovudine. Other NRTIs (nucleoside reverse
      transcriptase inhibitors) or NNRTIs may be used at the discretion of the Investigator, but
      will not be provided by the Sponsor. The Baseline Visit (Day 1) will be followed by a 48-week
      treatment period during which patients will be evaluated at Weeks 4, 8, 12, 16, 24, 36, 48
      and at a final Follow-Up Visit during Week 52. (total of 10 visits from Screening to final
      visit). At a number of visits throughout the study, blood samples will be obtained to assess
      defined laboratory values, safety parameters and to determine concentrations of study drugs
      darunavir, TMC125 (if applicable) and ritonavir). Patients will be assessed for change in CD4
      count and HIV-RNA throughout the study. At each visit, vital signs will be assessed and
      patients will be asked about any untoward medical occurrences and these will be recorded as
      adverse events (AEs) and/or HIV-related events. Detailed definitions and reporting procedures
      for AEs will be provided as part of the protocol. Study patients will receive PREZISTA
      (darunavir) 600 mg boosted with 100 mg of ritonavir orally (by mouth) twice a day in
      combination with other antiretroviral drugs for 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Viral Load (VL) &lt; 50 HIV-1 RNA Copies/mL (Time to Loss of Virologic Response[TLOVR]) Subjects by Sex</measure>
    <time_frame>Week 48</time_frame>
    <description>TLOVR - responders/non-responders per FDA TLOVR response algorithm. A subject was considered a responder at that time point and that subsequent. A subject was considered a non-responder at a time point in the following situations: discontinued treatment at that time point, a rebound value at that time point and that subsequent or at that time point and that followed by treatment discontinuation, intermittent missing values were considered a response if the immediately preceding and following visits were a response, rebound at earlier time point, or any new, unplanned ARV except in tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of TLOVR Non-virologic Failure (VF) Censored - VL &lt; 50 HIV-1 RNA Subjects by Sex</measure>
    <time_frame>Week 48</time_frame>
    <description>TLOVR non-virologic failure (VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of VL &lt; 50 HIV-1 RNA Copies/mL (TLOVR) Subjects by Race</measure>
    <time_frame>Week 48</time_frame>
    <description>Intention to Treat population (ITT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Etravirine-TMC125 (ETR) Subgroup- VL &lt; 50 HIV-1 RNA Copies/mL (TLOVR) Subjects</measure>
    <time_frame>Week 48</time_frame>
    <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Statistics of [TLOVR Non-virologic Failure (VF) Censored] - VL &lt; 50 HIV-1 RNA by Race</measure>
    <time_frame>Week 48</time_frame>
    <description>TLOVR non-virologic failure (VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Statistics of ETR Subgroup [TLOVR Non-virologic Failure (VF) Censored] - VL &lt; 50 HIV-1 RNA</measure>
    <time_frame>Week 48</time_frame>
    <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)
TLOVR non-virologic failure(VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Statistics of Change From Baseline in CD4+ Cell Count Using Observed Values</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Observed obsevations have no imputation methods applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Statistics of ETR Subgroup - Change From Baseline in CD4+ Cell Using Observed Values</measure>
    <time_frame>Week 48</time_frame>
    <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Statistics of Change From Baseline in CD4+ Cell Count Using the Imputation Method of Last Observation Carried Forward (LOCF)</measure>
    <time_frame>Week 48</time_frame>
    <description>Last Observation Carried Forward (LOCF) imputation method applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Statistics of ETR Subgroup - Change From Baseline in CD4+ Cell Count Using the Imputation Method of LOCF</measure>
    <time_frame>Week 48</time_frame>
    <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR). The Last Observation Carried Forward (LOCF) imputation method was applied.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">429</enrollment>
  <condition>HIV</condition>
  <condition>Infectious</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>darunavir 600mg bid for 48 wks,ritonavir 100mg bid for 48 wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darunavir</intervention_name>
    <description>600mg bid for 48 wks</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>100mg bid for 48 wks</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV infection

          -  Plasma HIV-RNA &gt;= 1000 copies/mL

          -  Must be able to comply with protocol requirements

        Exclusion Criteria:

          -  No prior use of PREZISTA (darunavir), TMC125, enfuvirtide, or tipranavir

          -  No currently active AIDS defining illness, Category C conditions according to the
             Center for Disease Control [CDC] Classification System for HIV Infection (1993) with
             the following exceptions, which must be discussed with the Sponsor prior to
             enrollment: stable cutaneous Kaposi's Sarcoma, Wasting syndrome due to HIV infection

          -  Not currently using an investigational drug

          -  Not pregnant or breastfeeding

          -  No Grade 3 or 4 laboratory abnormality as defined by DAIDS (Division of AIDS, National
             Institute of Allergy and Infectious Diseases).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port St Lucie</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio Piedras</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2006</study_first_submitted>
  <study_first_submitted_qc>September 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2006</study_first_posted>
  <results_first_submitted>November 24, 2009</results_first_submitted>
  <results_first_submitted_qc>September 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2010</results_first_posted>
  <last_update_submitted>April 2, 2014</last_update_submitted>
  <last_update_submitted_qc>April 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Immunodeficiency Virus, Human</keyword>
  <keyword>Females</keyword>
  <keyword>Women</keyword>
  <keyword>PREZISTA</keyword>
  <keyword>darunavir</keyword>
  <keyword>TMC114</keyword>
  <keyword>Protease Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Female</title>
          <description>darunavir 600 milligram (mg) twice daily dosing (bid) for 48 weeks administered with ritonavir 100 mg bid for 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Male</title>
          <description>darunavir 600 mg twice bid for 48 weeks administered with ritonavir 100 mg bid for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE/HIV-related event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Adherence</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Virologic failure</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible to continue the trial</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician's decision to close the site</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject moved out of state</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject taking too many different meds</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No virologic response by week 12</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject was too busy for appointments</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject did not continue visits</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject primary physician's decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Female</title>
          <description>darunavir (DRV) 600 mg bid for 48 weeks administered with ritonavir 100 mg bid for 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Male</title>
          <description>darunavir (DRV) 600 mg bid for 48 weeks administered with ritonavir 100 mg bid for 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="287"/>
            <count group_id="B2" value="142"/>
            <count group_id="B3" value="429"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="19" upper_limit="78"/>
                    <measurement group_id="B2" value="45" lower_limit="21" upper_limit="78"/>
                    <measurement group_id="B3" value="43" lower_limit="19" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian/White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Antiretroviral (ARV) Experience: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NNRTI: &lt; 1 drug count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NNRTI: &gt;= 1 drug count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous ARV experience: Protease inhibitor (PI)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PI: &lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PI: &gt;=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ cell count</title>
          <units>cells/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210" lower_limit="1" upper_limit="868"/>
                    <measurement group_id="B2" value="175" lower_limit="2" upper_limit="1125"/>
                    <measurement group_id="B3" value="200" lower_limit="1" upper_limit="1125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma log10 copies/mL VL HIV-1 RNA</title>
          <units>copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.65" spread="0.883"/>
                    <measurement group_id="B2" value="4.73" spread="0.856"/>
                    <measurement group_id="B3" value="4.67" spread="0.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since HIV-infection diagnosis</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.78" lower_limit="0.29" upper_limit="27.62"/>
                    <measurement group_id="B2" value="11.91" lower_limit="1.21" upper_limit="23.76"/>
                    <measurement group_id="B3" value="11.3" lower_limit="0.29" upper_limit="27.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Viral Load (VL) &lt; 50 HIV-1 RNA Copies/mL (Time to Loss of Virologic Response[TLOVR]) Subjects by Sex</title>
        <description>TLOVR - responders/non-responders per FDA TLOVR response algorithm. A subject was considered a responder at that time point and that subsequent. A subject was considered a non-responder at a time point in the following situations: discontinued treatment at that time point, a rebound value at that time point and that subsequent or at that time point and that followed by treatment discontinuation, intermittent missing values were considered a response if the immediately preceding and following visits were a response, rebound at earlier time point, or any new, unplanned ARV except in tolerability</description>
        <time_frame>Week 48</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Female</title>
            <description>darunavir (DRV) 600 mg bid for 48 weeks administered with ritonavir 100 mg bid for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Male</title>
            <description>darunavir (DRV) 600 mg bid for 48 weeks administered with ritonavir 100 mg bid for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Viral Load (VL) &lt; 50 HIV-1 RNA Copies/mL (Time to Loss of Virologic Response[TLOVR]) Subjects by Sex</title>
          <description>TLOVR - responders/non-responders per FDA TLOVR response algorithm. A subject was considered a responder at that time point and that subsequent. A subject was considered a non-responder at a time point in the following situations: discontinued treatment at that time point, a rebound value at that time point and that subsequent or at that time point and that followed by treatment discontinuation, intermittent missing values were considered a response if the immediately preceding and following visits were a response, rebound at earlier time point, or any new, unplanned ARV except in tolerability</description>
          <population>Intention to Treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Confidence interval of the difference in proportion of response between two sexes estimated by:
Application of delta method to be obtained Standard Error (SE)
Calculation of lower and upper bound using normal approximation to the difference in response rates</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Test for non-inferiority (Delta=15%)</non_inferiority_desc>
            <p_value>0.30</p_value>
            <p_value_desc>P-Value for difference (Female - Male): Test for non-inferiority (Delta=15%)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Estimates from logistic regression analysis include baseline log10 viral load and baseline CD4 cell count as covariates and gender as a factor.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.052</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.85</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of VL &lt; 50 HIV-1 RNA Copies/mL (TLOVR) Subjects by Race</title>
        <description>Intention to Treat population (ITT)</description>
        <time_frame>Week 48</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Black</title>
          </group>
          <group group_id="O2">
            <title>Caucasian</title>
          </group>
          <group group_id="O3">
            <title>Hispanic</title>
          </group>
          <group group_id="O4">
            <title>Asian</title>
          </group>
          <group group_id="O5">
            <title>Other</title>
          </group>
        </group_list>
        <measure>
          <title>Number of VL &lt; 50 HIV-1 RNA Copies/mL (TLOVR) Subjects by Race</title>
          <description>Intention to Treat population (ITT)</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Etravirine-TMC125 (ETR) Subgroup- VL &lt; 50 HIV-1 RNA Copies/mL (TLOVR) Subjects</title>
        <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)</description>
        <time_frame>Week 48</time_frame>
        <population>ETR Subgroup- Intention to Treat population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Female</title>
          </group>
          <group group_id="O2">
            <title>Male</title>
          </group>
          <group group_id="O3">
            <title>Black</title>
          </group>
          <group group_id="O4">
            <title>Caucasian</title>
          </group>
          <group group_id="O5">
            <title>Hispanic</title>
          </group>
          <group group_id="O6">
            <title>Asian</title>
          </group>
          <group group_id="O7">
            <title>Other</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Etravirine-TMC125 (ETR) Subgroup- VL &lt; 50 HIV-1 RNA Copies/mL (TLOVR) Subjects</title>
          <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)</description>
          <population>ETR Subgroup- Intention to Treat population (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" spread="0.088"/>
                    <measurement group_id="O2" value="54" spread="0.131"/>
                    <measurement group_id="O3" value="74" spread="0.092"/>
                    <measurement group_id="O4" value="21" spread="0.191"/>
                    <measurement group_id="O5" value="25" spread="0.158"/>
                    <measurement group_id="O6" value="2" spread="0.472"/>
                    <measurement group_id="O7" value="1" spread="-1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Descriptive Statistics of [TLOVR Non-virologic Failure (VF) Censored] - VL &lt; 50 HIV-1 RNA by Race</title>
        <description>TLOVR non-virologic failure (VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.</description>
        <time_frame>Week 48</time_frame>
        <population>TLOVR Non-virologic Failure(VF) Censored</population>
        <group_list>
          <group group_id="O1">
            <title>Black</title>
          </group>
          <group group_id="O2">
            <title>Caucasian</title>
          </group>
          <group group_id="O3">
            <title>Hispanic</title>
          </group>
          <group group_id="O4">
            <title>Asian</title>
          </group>
          <group group_id="O5">
            <title>Other</title>
          </group>
        </group_list>
        <measure>
          <title>Descriptive Statistics of [TLOVR Non-virologic Failure (VF) Censored] - VL &lt; 50 HIV-1 RNA by Race</title>
          <description>TLOVR non-virologic failure (VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.</description>
          <population>TLOVR Non-virologic Failure(VF) Censored</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Descriptive Statistics of ETR Subgroup [TLOVR Non-virologic Failure (VF) Censored] - VL &lt; 50 HIV-1 RNA</title>
        <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)
TLOVR non-virologic failure(VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.</description>
        <time_frame>Week 48</time_frame>
        <population>Etravirine-TMC125 (ETR) Subgroup [TLOVR Non-virologic Failure (VF) Censored]</population>
        <group_list>
          <group group_id="O1">
            <title>Female</title>
          </group>
          <group group_id="O2">
            <title>Male</title>
          </group>
          <group group_id="O3">
            <title>Black</title>
          </group>
          <group group_id="O4">
            <title>Caucasian</title>
          </group>
          <group group_id="O5">
            <title>Hispanic</title>
          </group>
          <group group_id="O6">
            <title>Asian</title>
          </group>
          <group group_id="O7">
            <title>Other</title>
          </group>
        </group_list>
        <measure>
          <title>Descriptive Statistics of ETR Subgroup [TLOVR Non-virologic Failure (VF) Censored] - VL &lt; 50 HIV-1 RNA</title>
          <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)
TLOVR non-virologic failure(VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.</description>
          <population>Etravirine-TMC125 (ETR) Subgroup [TLOVR Non-virologic Failure (VF) Censored]</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Descriptive Statistics of Change From Baseline in CD4+ Cell Count Using Observed Values</title>
        <description>Observed obsevations have no imputation methods applied.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Female</title>
          </group>
          <group group_id="O2">
            <title>Male</title>
          </group>
          <group group_id="O3">
            <title>Black</title>
          </group>
          <group group_id="O4">
            <title>Caucasian</title>
          </group>
          <group group_id="O5">
            <title>Hispanic</title>
          </group>
          <group group_id="O6">
            <title>Asian</title>
          </group>
          <group group_id="O7">
            <title>Other</title>
          </group>
        </group_list>
        <measure>
          <title>Descriptive Statistics of Change From Baseline in CD4+ Cell Count Using Observed Values</title>
          <description>Observed obsevations have no imputation methods applied.</description>
          <population>ITT</population>
          <units>x10^6 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="173"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" spread="11.2"/>
                    <measurement group_id="O2" value="122" spread="12.3"/>
                    <measurement group_id="O3" value="143" spread="10.8"/>
                    <measurement group_id="O4" value="151" spread="23.8"/>
                    <measurement group_id="O5" value="133" spread="17.0"/>
                    <measurement group_id="O6" value="45" spread="24.5"/>
                    <measurement group_id="O7" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Descriptive Statistics of ETR Subgroup - Change From Baseline in CD4+ Cell Using Observed Values</title>
        <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)</description>
        <time_frame>Week 48</time_frame>
        <population>Etravirine-TMC125 (ETR Subgroup) Intention to Treat population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Female</title>
          </group>
          <group group_id="O2">
            <title>Male</title>
          </group>
          <group group_id="O3">
            <title>Black</title>
          </group>
          <group group_id="O4">
            <title>Caucasian</title>
          </group>
          <group group_id="O5">
            <title>Hispanic</title>
          </group>
          <group group_id="O6">
            <title>Asian</title>
          </group>
          <group group_id="O7">
            <title>Other</title>
          </group>
        </group_list>
        <measure>
          <title>Descriptive Statistics of ETR Subgroup - Change From Baseline in CD4+ Cell Using Observed Values</title>
          <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR)</description>
          <population>Etravirine-TMC125 (ETR Subgroup) Intention to Treat population (ITT)</population>
          <units>x10^6 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" spread="15.8"/>
                    <measurement group_id="O2" value="108" spread="15.1"/>
                    <measurement group_id="O3" value="135" spread="13.5"/>
                    <measurement group_id="O4" value="111" spread="26.7"/>
                    <measurement group_id="O5" value="98" spread="29.8"/>
                    <measurement group_id="O6" value="45" spread="24.5"/>
                    <measurement group_id="O7" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Descriptive Statistics of Change From Baseline in CD4+ Cell Count Using the Imputation Method of Last Observation Carried Forward (LOCF)</title>
        <description>Last Observation Carried Forward (LOCF) imputation method applied.</description>
        <time_frame>Week 48</time_frame>
        <population>ITT LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Female</title>
          </group>
          <group group_id="O2">
            <title>Male</title>
          </group>
          <group group_id="O3">
            <title>Black</title>
          </group>
          <group group_id="O4">
            <title>Caucasian</title>
          </group>
          <group group_id="O5">
            <title>Hispanic</title>
          </group>
          <group group_id="O6">
            <title>Asian</title>
          </group>
          <group group_id="O7">
            <title>Other</title>
          </group>
        </group_list>
        <measure>
          <title>Descriptive Statistics of Change From Baseline in CD4+ Cell Count Using the Imputation Method of Last Observation Carried Forward (LOCF)</title>
          <description>Last Observation Carried Forward (LOCF) imputation method applied.</description>
          <population>ITT LOCF</population>
          <units>x10^6 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="8.8"/>
                    <measurement group_id="O2" value="103" spread="11.2"/>
                    <measurement group_id="O3" value="109" spread="8.9"/>
                    <measurement group_id="O4" value="110" spread="20.4"/>
                    <measurement group_id="O5" value="109" spread="13.5"/>
                    <measurement group_id="O6" value="45" spread="24.5"/>
                    <measurement group_id="O7" value="138" spread="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of TLOVR Non-virologic Failure (VF) Censored - VL &lt; 50 HIV-1 RNA Subjects by Sex</title>
        <description>TLOVR non-virologic failure (VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.</description>
        <time_frame>Week 48</time_frame>
        <population>TLOVR non-virologic failure (VF) censored</population>
        <group_list>
          <group group_id="O1">
            <title>Female</title>
            <description>darunavir (DRV) 600 mg bid for 48 weeks administered with ritonavir 100 mg bid for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Male</title>
            <description>darunavir (DRV) 600 mg bid for 48 weeks administered with ritonavir 100 mg bid for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of TLOVR Non-virologic Failure (VF) Censored - VL &lt; 50 HIV-1 RNA Subjects by Sex</title>
          <description>TLOVR non-virologic failure (VF) censored. This imputation method differs from the TLOVR algorithm, because subjects that dropped out for reasons other than virologic failure were censored from the time of discontinuation onwards.</description>
          <population>TLOVR non-virologic failure (VF) censored</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Descriptive Statistics of ETR Subgroup - Change From Baseline in CD4+ Cell Count Using the Imputation Method of LOCF</title>
        <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR). The Last Observation Carried Forward (LOCF) imputation method was applied.</description>
        <time_frame>Week 48</time_frame>
        <population>Etravirine-TMC125 (ETR Subgroup) Intention to Treat population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Female</title>
          </group>
          <group group_id="O2">
            <title>Male</title>
          </group>
          <group group_id="O3">
            <title>Black</title>
          </group>
          <group group_id="O4">
            <title>Caucasian</title>
          </group>
          <group group_id="O5">
            <title>Hispanic</title>
          </group>
          <group group_id="O6">
            <title>Asian</title>
          </group>
          <group group_id="O7">
            <title>Other</title>
          </group>
        </group_list>
        <measure>
          <title>Descriptive Statistics of ETR Subgroup - Change From Baseline in CD4+ Cell Count Using the Imputation Method of LOCF</title>
          <description>The Etravirine-TMC125 (ETR Subgroup population was defined as all ITT subjects who took at least 1 dose of ETR). The Last Observation Carried Forward (LOCF) imputation method was applied.</description>
          <population>Etravirine-TMC125 (ETR Subgroup) Intention to Treat population (ITT)</population>
          <units>x10^6 Cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="12.7"/>
                    <measurement group_id="O2" value="98" spread="14.0"/>
                    <measurement group_id="O3" value="113" spread="12.1"/>
                    <measurement group_id="O4" value="84" spread="21.7"/>
                    <measurement group_id="O5" value="90" spread="22.6"/>
                    <measurement group_id="O6" value="45" spread="24.5"/>
                    <measurement group_id="O7" value="138" spread="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Female</title>
          <description>darunavir (DRV) 600 mg bid for 48 weeks administered with ritonavir 100 mg bid for 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Male</title>
          <description>darunavir (DRV) 600 mg bid for 48 weeks administered with ritonavir 100 mg bid for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cardiac Failures Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired Oesophageal Web</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gatrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oesophageal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Abcess Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bacterial Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bartonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastroenteriris Cryptosporidial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lung Infection Pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Meningitis Aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Meningitis Tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Meningitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oesophageal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumocystis Jiroveci Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonia Legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rectal Abcess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Septic Arthritis Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sinusitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Staphylococcal Abcess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Staphylococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Operative Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Amino Transferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Aspartate Amino Transferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood Amylase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood Lactic Acid Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lactic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal Cancer Stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vulval Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Status Epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pre-Eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Premature Labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Catatonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Conversion Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioneurotic Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Drug Abuser</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vascular Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If TTCA does not publish within 12 months after study conclusion or after TTCA confirms there will be no multicenter publication, Institution may publish their results from their site individually, provided TTCA has 60 day review for confidentiality and additional 60 day delay for patent application.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Tibotec Therapeutics Clinical Affairs</name_or_title>
      <organization>Tibotec Therapeutics Clinical Affairs (TTCA), Division of Centocor Ortho Biotech Services, LLC</organization>
      <phone>877-732-2488</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

